HRP20190107T1 - Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens - Google Patents

Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens

Info

Publication number
HRP20190107T1
HRP20190107T1 HRP20190107TT HRP20190107T HRP20190107T1 HR P20190107 T1 HRP20190107 T1 HR P20190107T1 HR P20190107T T HRP20190107T T HR P20190107TT HR P20190107 T HRP20190107 T HR P20190107T HR P20190107 T1 HRP20190107 T1 HR P20190107T1
Authority
HR
Croatia
Prior art keywords
anticancerogenic
diamino
quinoline
substituted
agents
Prior art date
Application number
HRP20190107TT
Other languages
English (en)
Croatian (hr)
Inventor
Firas BASSISSI
Antoine Beret
Sonia BRUN
Jérôme Courcambeck
Clarisse DUBRAY
Gregory NICOLAS
Philippe Halfon
Original Assignee
Genoscience Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma Sas filed Critical Genoscience Pharma Sas
Publication of HRP20190107T1 publication Critical patent/HRP20190107T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20190107TT 2014-10-31 2015-10-26 Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens HRP20190107T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
PCT/IB2015/002438 WO2016067112A1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents
EP15837091.6A EP3212629B1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents

Publications (1)

Publication Number Publication Date
HRP20190107T1 true HRP20190107T1 (hr) 2019-03-08

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190107TT HRP20190107T1 (hr) 2014-10-31 2015-10-26 Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens

Country Status (34)

Country Link
US (1) US10722505B2 (enExample)
EP (1) EP3212629B1 (enExample)
JP (1) JP6588546B2 (enExample)
KR (1) KR102548547B1 (enExample)
CN (1) CN107148416B (enExample)
AU (1) AU2015338844B2 (enExample)
CA (1) CA2965262C (enExample)
CL (1) CL2017001073A1 (enExample)
CO (1) CO2017007325A2 (enExample)
CR (1) CR20170177A (enExample)
CY (1) CY1121326T1 (enExample)
DK (1) DK3212629T3 (enExample)
DO (1) DOP2017000107A (enExample)
EA (1) EA037119B1 (enExample)
EC (1) ECSP17026748A (enExample)
ES (1) ES2707125T3 (enExample)
GE (1) GEP20207108B (enExample)
HR (1) HRP20190107T1 (enExample)
IL (1) IL251775B (enExample)
LT (1) LT3212629T (enExample)
MA (1) MA40875B1 (enExample)
MY (1) MY193740A (enExample)
NI (1) NI201700052A (enExample)
PE (1) PE20191142A1 (enExample)
PH (1) PH12017500810A1 (enExample)
PL (1) PL3212629T3 (enExample)
PT (1) PT3212629T (enExample)
RS (1) RS58328B1 (enExample)
SG (1) SG11201703479SA (enExample)
SI (1) SI3212629T1 (enExample)
TN (1) TN2017000168A1 (enExample)
TR (1) TR201900148T4 (enExample)
UA (1) UA122062C2 (enExample)
WO (1) WO2016067112A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2849560T3 (es) * 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TW202214244A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 具有協同抗癌功效之氯硝柳胺(Niclosamide)和雙硫侖(Disulfiram)醫藥組合物及其用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers
EP4520396A1 (en) 2023-09-05 2025-03-12 Genoscience Pharma Crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
RS60244B1 (sr) * 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
SG11201506385WA (en) * 2013-03-18 2015-10-29 Genoscience Pharma Quinolines derivatives as novel anticancer agents

Also Published As

Publication number Publication date
CN107148416B (zh) 2020-05-05
CA2965262A1 (en) 2016-05-06
BR112017018637A2 (pt) 2022-07-05
US10722505B2 (en) 2020-07-28
ECSP17026748A (es) 2018-03-31
PE20191142A1 (es) 2019-09-02
KR102548547B1 (ko) 2023-06-27
PH12017500810A1 (en) 2017-10-02
JP2017538673A (ja) 2017-12-28
JP6588546B2 (ja) 2019-10-09
KR20170077160A (ko) 2017-07-05
IL251775A0 (en) 2017-06-29
GEP20207108B (en) 2020-05-11
SG11201703479SA (en) 2017-05-30
IL251775B (en) 2020-07-30
NI201700052A (es) 2017-09-11
MY193740A (en) 2022-10-27
CL2017001073A1 (es) 2018-01-12
DK3212629T3 (en) 2019-02-18
CA2965262C (en) 2023-03-14
PT3212629T (pt) 2019-02-04
SI3212629T1 (sl) 2019-02-28
EA201790949A1 (ru) 2018-02-28
US20190314359A1 (en) 2019-10-17
EA037119B1 (ru) 2021-02-09
TR201900148T4 (tr) 2019-02-21
RS58328B1 (sr) 2019-03-29
AU2015338844A1 (en) 2017-05-04
EP3212629A1 (en) 2017-09-06
MA40875B1 (fr) 2019-01-31
ES2707125T3 (es) 2019-04-02
GEAP202014494A (en) 2020-01-27
MA40875A (fr) 2017-09-06
LT3212629T (lt) 2019-01-10
NZ731345A (en) 2023-09-29
UA122062C2 (uk) 2020-09-10
TN2017000168A1 (en) 2018-10-19
AU2015338844B2 (en) 2019-09-19
CN107148416A (zh) 2017-09-08
CR20170177A (es) 2017-09-19
DOP2017000107A (es) 2017-09-15
PL3212629T3 (pl) 2019-05-31
CO2017007325A2 (es) 2017-10-20
WO2016067112A1 (en) 2016-05-06
CY1121326T1 (el) 2020-05-29
EP3212629B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
IL283979B (en) 3,1-thiazol-2-yl converted benzamides
DK3377082T3 (da) Sammensætninger, der omfatter bakteriestammer
ZA201605622B (en) 1,3-benzodioxole derivative
LT3549592T (lt) Kompozicijos, apimančios bakterijų kamienus
DK3360558T3 (da) Sammensætninger omfattende bakteriestammer
LT3307288T (lt) Kompozicijos, apimančios bakterijų kamienus
LT3206700T (lt) Kompozicijos, apimančios bakterijų kamienus
LT3177149T (lt) Bakterijų sporų kompozicijos, skirtos pramoniniam panaudojimui
HRP20190107T1 (hr) Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens
LT3273947T (lt) Kompozicija, skirta akių sveikatai
HRP20181530T1 (hr) Novi sulfonilaminobenzamidni spojevi
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu
FI20140112A7 (fi) Maatalouskone
PL3086100T3 (pl) Waga z podwójną skalą
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DK3119380T3 (da) Sammensætning omfattende biprodukter
ITUA20162099A1 (it) Macchina per tempra
UA32431S (uk) Стрем'янка
ITUB201551290U1 (it) Ovie' oviel
SG10201402964RA (en) Dehydration of 2,3-butanediole
UA29419S (uk) Губка на господарські потреби
TH1501005582A (th) เครื่องแจกจ่าย
TH1601001602A (th) ส่วนด้ามจับสำหรับแปรงสีฟันและวิธีการผลิตนั้นตลอดจนแปรงสีฟัน
ES1117255Y (es) Cepillo de dientes
CO6910172A2 (es) Cepillo de dientes